Impact of high on‐aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug‐eluting stents
暂无分享,去创建一个
Peter L Duffy | G. Stone | T. Henry | A. Kirtane | F. Neumann | G. Weisz | R. Mehran | M. Rinaldi | B. Brodie | D. Cox | T. Stuckey | B. Witzenbichler | P. Duffy | E. Mazzaferri | C. Metzger | Christine J. Chung | Yiran Zhang | Christine J Chung | Yiran Zhang
[1] Peter L Duffy,et al. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. , 2017, JACC. Cardiovascular interventions.
[2] Deepak L. Bhatt,et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.
[3] E. Ohman,et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial , 2017, The Lancet.
[4] S. Pocock,et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.
[5] Jun-Jie Zhang,et al. High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention , 2016, BMC Cardiovascular Disorders.
[6] P. Serruys,et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[7] G. Lip,et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.
[8] J. Cigarroa,et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, The Journal of thoracic and cardiovascular surgery.
[9] M. Price,et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.
[10] H. Schunkert,et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. , 2014, Journal of the American College of Cardiology.
[11] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[12] H. Hussein,et al. Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures , 2013, American Journal of Neuroradiology.
[13] Tom Adriaenssens,et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.
[14] G. Stone,et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.
[15] T. Warner,et al. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. , 2011, British journal of clinical pharmacology.
[16] P. Teirstein,et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.
[17] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[18] R. Ferrari,et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. , 2010, Journal of the American College of Cardiology.
[19] J. T. ten Berg,et al. High on‐aspirin platelet reactivity as measured with aggregation‐based, cyclooxygenase‐1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events , 2010, Journal of thrombosis and haemostasis : JTH.
[20] M. Furman,et al. Response to Letter Regarding Article, “Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization” , 2010 .
[21] J. Kojuri,et al. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. , 2010, Cardiovascular therapeutics.
[22] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[23] J. Heemskerk,et al. Platelet response heterogeneity in thrombus formation , 2009, Thrombosis and Haemostasis.
[24] E. Grove,et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. , 2008, Thrombosis research.
[25] M. Fromm,et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.
[26] S. Ragot,et al. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[27] C. Lau,et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. , 2007, The American journal of medicine.
[28] F. Neumann,et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.
[29] A. Gori,et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. , 2006, The American journal of cardiology.
[30] R. Collins,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[31] P. Gurbel,et al. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. , 2005, Journal of the American College of Cardiology.
[32] A. Jacobs,et al. Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.
[33] C. Lau,et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.
[34] Z. Vered,et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? , 2004, American heart journal.
[35] J. Herbert,et al. P2Y12, A New Platelet ADP Receptor, Target of Clopidogrel , 2003, Seminars in vascular medicine.
[36] E. Topol,et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.
[37] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[38] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[39] E. Topol,et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.
[40] P. Serruys,et al. Stent thrombosis. , 2010, Journal of the American College of Cardiology.
[41] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .